Compare ASIX & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASIX | CGC |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 460.1M | 389.2M |
| IPO Year | 2016 | 2023 |
| Metric | ASIX | CGC |
|---|---|---|
| Price | $15.68 | $0.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $20.00 | $1.96 |
| AVG Volume (30 Days) | 212.4K | ★ 2.2M |
| Earning Date | 11-04-2026 | 11-06-2026 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | 11.11 | ★ 84.17 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,684,625,000.00 | $12,759,000.00 |
| Revenue This Year | $9.86 | $21.39 |
| Revenue Next Year | $5.06 | $8.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 45.49 | N/A |
| 52 Week Low | $14.10 | $0.65 |
| 52 Week High | $26.73 | $2.38 |
| Indicator | ASIX | CGC |
|---|---|---|
| Relative Strength Index (RSI) | 39.57 | 22.69 |
| Support Level | $15.46 | N/A |
| Resistance Level | $16.93 | $1.08 |
| Average True Range (ATR) | 0.44 | 0.05 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 30.73 | 9.88 |
AdvanSix Inc is a diversified chemistry company playing a critical role in international supply chains, innovating and delivering essential products for customers across a wide variety of end markets and applications that touch people's lives, including building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives, and electronics. The company's key products include Nylon, Caprolactam, Plant Nutrients, and Chemical Intermediates. The majority of sales are from Plant Nutrients products. The company operates in the United States and internationally, with the majority of revenue coming from the United States.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.